{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:40:11Z","timestamp":1794490811261,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000783","name":"EC | Research Executive Agency","doi-asserted-by":"publisher","award":["860003"],"award-info":[{"award-number":["860003"]}],"id":[{"id":"10.13039\/501100000783","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HU 1838\/1-1"],"award-info":[{"award-number":["HU 1838\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HU 1838\/2-1"],"award-info":[{"award-number":["HU 1838\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BMS Foundation - Grant FA-19-009","id":[{"id":"https:\/\/ror.org\/02nrv4053","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Treatment of advanced melanoma with combined PD-1\/CTLA-4 blockade commonly causes serious immune-mediated complications. Here, we identify a subset of patients predisposed to immune checkpoint blockade-related hepatitis who are distinguished by chronic expansion of effector memory CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells (T\n                    <jats:sub>EM<\/jats:sub>\n                    cells). Pre-therapy CD4\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>EM<\/jats:sub>\n                    cell expansion occurs primarily during autumn or winter in patients with metastatic disease and high cytomegalovirus (CMV)-specific serum antibody titres. These clinical features implicate metastasis-dependent, compartmentalised CMV reactivation as the cause of CD4\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>EM<\/jats:sub>\n                    expansion. Pre-therapy CD4\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>EM<\/jats:sub>\n                    expansion predicts hepatitis in CMV-seropositive patients, opening possibilities for avoidance or prevention. 3 of 4 patients with pre-treatment CD4\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>EM<\/jats:sub>\n                    expansion who received \u03b1PD-1 monotherapy instead of \u03b1PD-1\/\u03b1CTLA-4 therapy remained hepatitis-free. 4 of 4 patients with baseline CD4\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>EM<\/jats:sub>\n                    expansion given prophylactic valganciclovir and \u03b1PD-1\/\u03b1CTLA-4 therapy remained hepatitis-free. Our findings exemplify how pathogen exposure can shape clinical reactions after cancer therapy and how this insight leads to therapeutic innovations.\n                  <\/jats:p>","DOI":"10.1038\/s41467-021-21572-y","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T06:03:59Z","timestamp":1614837839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1199-4210","authenticated-orcid":false,"given":"James A.","family":"Hutchinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kronenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Riquelme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8422-6581","authenticated-orcid":false,"given":"J\u00fcrgen J.","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1495-9162","authenticated-orcid":false,"given":"Gunther","family":"Glehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5506-3506","authenticated-orcid":false,"given":"Hannah-Lou","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Zeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Evert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schmiedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Mickler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Drexler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Bitterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Koestler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Burkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3874-0296","authenticated-orcid":false,"given":"Hans J.","family":"Schlitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3056-0143","authenticated-orcid":false,"given":"Dirk","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens M.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Spang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0059-0349","authenticated-orcid":false,"given":"Barbara","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward K.","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"21572_CR1","unstructured":"Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535\u20131546 (2019)."},{"key":"21572_CR2","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 20, 1239\u20131251 (2019).","journal-title":"Lancet Oncol."},{"key":"21572_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320\u2013330 (2015).","journal-title":"N. Engl. J. Med."},{"key":"21572_CR4","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006\u20132017 (2015).","journal-title":"N. Engl. J. Med."},{"key":"21572_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345\u20131356 (2017).","journal-title":"N. Engl. J. Med."},{"key":"21572_CR6","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi, F. S. et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 19, 1480\u20131492 (2018).","journal-title":"Lancet Oncol."},{"key":"21572_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158\u2013168 (2018).","journal-title":"N. Engl. J. Med."},{"key":"21572_CR8","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","volume":"35","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf, D. et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J. Clin. Oncol. 35, 3807\u20133814 (2017).","journal-title":"J. Clin. Oncol."},{"key":"21572_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","volume":"17","author":"JA Thompson","year":"2019","unstructured":"Thompson, J. A. et al. Management of immunotherapy-related toxicities, version 1.2019. J. Natl Compr. Canc Netw. 17, 255\u2013289 (2019).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"21572_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.canlet.2019.04.018","volume":"456","author":"A Teufel","year":"2019","unstructured":"Teufel, A. et al. Management of immune related adverse events induced by immune checkpoint inhibition. Cancer Lett. 456, 80\u201387 (2019).","journal-title":"Cancer Lett."},{"key":"21572_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"21572_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122\u2013133 (2013).","journal-title":"N. Engl. J. Med."},{"key":"21572_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.immuni.2019.01.016","volume":"50","author":"J Ruotsalainen","year":"2019","unstructured":"Ruotsalainen, J. & Tuting, T. Live or let die: t cell survival in cancer immunotherapy. Immunity 50, 280\u2013282 (2019).","journal-title":"Immunity"},{"key":"21572_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","volume":"569","author":"E Perez-Ruiz","year":"2019","unstructured":"Perez-Ruiz, E. et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569, 428\u2013432 (2019).","journal-title":"Nature"},{"key":"21572_CR15","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1158\/2326-6066.CIR-18-0487","volume":"6","author":"A Young","year":"2018","unstructured":"Young, A., Quandt, Z. & Bluestone, J. A. The balancing act between cancer immunity and autoimmunity in response to immunotherapy. Cancer Immunol. Res. 6, 1445\u20131452 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"21572_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2, 234\u2013240 (2016).","journal-title":"JAMA Oncol."},{"key":"21572_CR17","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","volume":"77","author":"DY Oh","year":"2017","unstructured":"Oh, D. Y. et al. Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire. Cancer Res. 77, 1322\u20131330 (2017).","journal-title":"Cancer Res."},{"key":"21572_CR18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541\u2013547 (1995).","journal-title":"Immunity"},{"key":"21572_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14321","volume":"8","author":"BA Krishna","year":"2017","unstructured":"Krishna, B. A. et al. Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein. Nat. Commun. 8, 14321 (2017).","journal-title":"Nat. Commun."},{"key":"21572_CR20","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/ajt.14042","volume":"17","author":"M Peghin","year":"2017","unstructured":"Peghin, M. et al. Epidemiology and immediate indirect effects of respiratory viruses in lung transplant recipients: a 5-year prospective study. Am. J. Transplant. 17, 1304\u20131312 (2017).","journal-title":"Am. J. Transplant."},{"key":"21572_CR21","doi-asserted-by":"publisher","first-page":"578","DOI":"10.5694\/mja14.00183","volume":"201","author":"D Lancini","year":"2014","unstructured":"Lancini, D., Faddy, H. M., Flower, R. & Hogan, C. Cytomegalovirus disease in immunocompetent adults. Med. J. Aust. 201, 578\u2013580 (2014).","journal-title":"Med. J. Aust."},{"key":"21572_CR22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/tid.12515","volume":"18","author":"J Coussement","year":"2016","unstructured":"Coussement, J. et al. When polymerase chain reaction does not help: cytomegalovirus pneumonitis associated with very low or undetectable viral load in both blood and bronchoalveolar lavage samples after lung transplantation. Transpl. Infect. Dis. 18, 284\u2013287 (2016).","journal-title":"Transpl. Infect. Dis."},{"key":"21572_CR23","doi-asserted-by":"publisher","first-page":"e1006507","DOI":"10.1371\/journal.ppat.1006507","volume":"13","author":"M Almanan","year":"2017","unstructured":"Almanan, M. et al. Tissue-specific control of latent CMV reactivation by regulatory T cells. PLoS Pathog. 13, e1006507 (2017).","journal-title":"PLoS Pathog."},{"key":"21572_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.antiviral.2019.06.004","volume":"168","author":"G Andrei","year":"2019","unstructured":"Andrei, G. et al. Persistent primary cytomegalovirus infection in a kidney transplant recipient: multi-drug resistant and compartmentalized infection leading to graft loss. Antiviral Res. 168, 203\u2013209 (2019).","journal-title":"Antiviral Res."},{"key":"21572_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jcv.2016.07.018","volume":"82","author":"SE Luck","year":"2016","unstructured":"Luck, S. E., Emery, V. C., Atkinson, C., Sharland, M. & Griffiths, P. D. Compartmentalized dynamics of cytomegalovirus replication in treated congenital infection. J. Clin. Virol. 82, 152\u2013158 (2016).","journal-title":"J. Clin. Virol."},{"key":"21572_CR26","doi-asserted-by":"crossref","unstructured":"Pardieck, I. N., Beyrend, G., Redeker, A. & Arens, R. Cytomegalovirus infection and progressive differentiation of effector-memory T cells. F1000Res 7 (2018).","DOI":"10.12688\/f1000research.15753.1"},{"key":"21572_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fimmu.2019.00197","volume":"10","author":"E Marchi","year":"2019","unstructured":"Marchi, E., Lee, L. N. & Klenerman, P. Inflation vs. exhaustion of antiviral CD8\u2009+\u2009T-cell populations in persistent infections: two sides of the same coin? Front. Immunol. 10, 197 (2019).","journal-title":"Front. Immunol."},{"key":"21572_CR28","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.celrep.2018.03.074","volume":"23","author":"CL Gordon","year":"2018","unstructured":"Gordon, C. L. et al. Induction and maintenance of CX3CR1-intermediate peripheral memory CD8(+) T cells by persistent viruses and vaccines. Cell Rep. 23, 768\u2013782 (2018).","journal-title":"Cell Rep."},{"key":"21572_CR29","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/eji.201747018","volume":"47","author":"N Makwana","year":"2017","unstructured":"Makwana, N. et al. CMV drives the expansion of highly functional memory T cells expressing NK-cell receptors in renal transplant recipients. Eur. J. Immunol. 47, 1324\u20131334 (2017).","journal-title":"Eur. J. Immunol."},{"key":"21572_CR30","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069\u20131086 (2018).","journal-title":"Cancer Discov."},{"key":"21572_CR31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"21572_CR32","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s10637-017-0534-0","volume":"36","author":"T Fujii","year":"2018","unstructured":"Fujii, T. et al. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest. New Drugs 36, 638\u2013646 (2018).","journal-title":"Invest. New Drugs"},{"key":"21572_CR33","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563\u2013567 (2014).","journal-title":"Nature"},{"key":"21572_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0452-y","volume":"8","author":"N Verloh","year":"2018","unstructured":"Verloh, N. et al. In vivo confirmation of altered hepatic glucose metabolism in patients with liver fibrosis\/cirrhosis by (18)F-FDG PET\/CT. EJNMMI Res. 8, 98 (2018).","journal-title":"EJNMMI Res."},{"key":"21572_CR35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature 571, 211\u2013218 (2019).","journal-title":"Nature"},{"key":"21572_CR36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417\u2013421 (2016).","journal-title":"Nature"},{"key":"21572_CR37","doi-asserted-by":"publisher","first-page":"e1002951","DOI":"10.1371\/journal.ppat.1002951","volume":"8","author":"E Caselli","year":"2012","unstructured":"Caselli, E. et al. Virologic and immunologic evidence supporting an association between HHV-6 and Hashimoto\u2019s thyroiditis. PLoS Pathog. 8, e1002951 (2012).","journal-title":"PLoS Pathog."},{"key":"21572_CR38","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1093\/cid\/ciw539","volume":"63","author":"M Del Castillo","year":"2016","unstructured":"Del Castillo, M. et al. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin. Infect. Dis. 63, 1490\u20131493 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"21572_CR39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ejca.2017.09.019","volume":"86","author":"C Franklin","year":"2017","unstructured":"Franklin, C. et al. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. Eur. J. Cancer 86, 248\u2013256 (2017).","journal-title":"Eur. J. Cancer"},{"key":"21572_CR40","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3389\/fimmu.2018.01082","volume":"9","author":"RW Wilkinson","year":"2018","unstructured":"Wilkinson, R. W. & Leishman, A. J. Further advances in cancer immunotherapy: going beyond checkpoint blockade. Front. Immunol. 9, 1082 (2018).","journal-title":"Front. Immunol."},{"key":"21572_CR41","doi-asserted-by":"publisher","first-page":"e1007890","DOI":"10.1371\/journal.ppat.1007890","volume":"15","author":"NA Contreras","year":"2019","unstructured":"Contreras, N. A. et al. Life-long control of cytomegalovirus (CMV) by T resident memory cells in the adipose tissue results in inflammation and hyperglycemia. PLoS Pathog. 15, e1007890 (2019).","journal-title":"PLoS Pathog."},{"key":"21572_CR42","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","volume":"25","author":"Z Wang","year":"2019","unstructured":"Wang, Z. et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat. Med. 25, 141\u2013151 (2019).","journal-title":"Nat. Med."},{"key":"21572_CR43","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/ni1227","volume":"6","author":"AL Marzo","year":"2005","unstructured":"Marzo, A. L. et al. Initial T cell frequency dictates memory CD8+ T cell lineage commitment. Nat. Immunol. 6, 793\u2013799 (2005).","journal-title":"Nat. Immunol."},{"key":"21572_CR44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/ni889","volume":"4","author":"EJ Wherry","year":"2003","unstructured":"Wherry, E. J. et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4, 225\u2013234 (2003).","journal-title":"Nat. Immunol."},{"key":"21572_CR45","doi-asserted-by":"publisher","first-page":"6694","DOI":"10.4049\/jimmunol.173.11.6694","volume":"173","author":"MA Williams","year":"2004","unstructured":"Williams, M. A. & Bevan, M. J. Shortening the infectious period does not alter expansion of CD8 T cells but diminishes their capacity to differentiate into memory cells. J. Immunol. 173, 6694\u20136702 (2004).","journal-title":"J. Immunol."},{"key":"21572_CR46","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.4049\/jimmunol.174.9.5341","volume":"174","author":"H van Faassen","year":"2005","unstructured":"van Faassen, H. et al. Reducing the stimulation of CD8+ T cells during infection with intracellular bacteria promotes differentiation primarily into a central (CD62LhighCD44high) subset. J. Immunol. 174, 5341\u20135350 (2005).","journal-title":"J. Immunol."},{"key":"21572_CR47","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1084\/jem.20041852","volume":"201","author":"DM Jelley-Gibbs","year":"2005","unstructured":"Jelley-Gibbs, D. M. et al. Repeated stimulation of CD4 effector T cells can limit their protective function. J. Exp. Med. 201, 1101\u20131112 (2005).","journal-title":"J. Exp. Med."},{"key":"21572_CR48","doi-asserted-by":"publisher","first-page":"7563","DOI":"10.4049\/jimmunol.178.12.7563","volume":"178","author":"DM Jelley-Gibbs","year":"2007","unstructured":"Jelley-Gibbs, D. M. et al. Persistent depots of influenza antigen fail to induce a cytotoxic CD8 T cell response. J. Immunol. 178, 7563\u20137570 (2007).","journal-title":"J. Immunol."},{"key":"21572_CR49","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.4049\/jimmunol.179.10.6704","volume":"179","author":"S Sarkar","year":"2007","unstructured":"Sarkar, S. et al. Strength of stimulus and clonal competition impact the rate of memory CD8 T cell differentiation. J. Immunol. 179, 6704\u20136714 (2007).","journal-title":"J. Immunol."},{"key":"21572_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08534-1","volume":"10","author":"PC Rosato","year":"2019","unstructured":"Rosato, P. C. et al. Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nat. Commun. 10, 567 (2019).","journal-title":"Nat. Commun."},{"key":"21572_CR51","unstructured":"Medicines and Healthcare Products Regulatory Agency. Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation. Drug Safety Update 13: No. 3. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/840565\/Oct-2019-PDF.pdf (2019)."},{"key":"21572_CR52","doi-asserted-by":"publisher","unstructured":"Kronenberg, K., Riquelme, P. & Hutchinson, J. A. Standard protocols for immune profiling of peripheral blood leucocyte subsets by flow cytometry using DuraClone IM reagents. Protocol Exchange https:\/\/doi.org\/10.21203\/rs.3.pex-757\/v1 (2021).","DOI":"10.21203\/rs.3.pex-757\/v1"},{"key":"21572_CR53","doi-asserted-by":"publisher","unstructured":"Riquelme, P. & Hutchinson, J. A. Standard protocols for detection of human CMV-specific T cells Protocol Exchange https:\/\/doi.org\/10.21203\/rs.3.pex-758\/v1 (2021).","DOI":"10.21203\/rs.3.pex-758\/v1"},{"key":"21572_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-016-0174-y","volume":"6","author":"F Hofheinz","year":"2016","unstructured":"Hofheinz, F. et al. An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET. EJNMMI Res. 6, 19 (2016).","journal-title":"EJNMMI Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21572-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21572-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21572-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T11:07:49Z","timestamp":1674990469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21572-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["21572"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-21572-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"assertion":[{"value":"28 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Open Access funding information has been added to this article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.H. declares he has\u00a0received consulting fees and speaker\u2019s honoraria from BMS and Merck Sharp & Dohme (MSD). All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1439"}}